Sagimet Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Sagimet Biosciences (SGMT).

Price Target Range — 13 Quarters

Analyst Consensus — 14 Analysts

2S.Buy

11Buy

1Sell

Consensus RatingBuy# Analysts14Avg. Consensus PT$25Upside to Avg. PT+208.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 5, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$29
Oct 2, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$25→$26
Oct 1, 2026	Oppenheimer	Jay Olson	PT Raise	Outperform	$33→$38
Oct 1, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$29→$27
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Reinstates	Sell	$7
Sep 9, 2026	Barclays	Eliana Merle	Upgrade	Equal-Weight→Overweight	$8→$18
Sep 9, 2026	Cantor Fitzgerald	Yanni Souroutzidis	Initiate	Overweight	$11
Aug 25, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$29
Aug 14, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$12→$29
Aug 12, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$49→$56
May 19, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$35→$12
May 4, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$28→$49
Apr 29, 2026	Guggenheim	Seamus Fernandez	PT Cut	Buy	$27→$25
Mar 11, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$29
Feb 3, 2026	Guggenheim	Seamus Fernandez	Initiate	Buy	$27
Feb 3, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$29
Jan 28, 2026	Barclays	Eliana Merle	Initiate	Equal-Weight	$8
Nov 14, 2025	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$33→$35
Oct 22, 2025	Clear Street	Kaveri Pohlman	Initiate	Buy	$29
Oct 2, 2025	Canaccord Genuity	Edward Nash	Maintained	Buy	$28

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $29 price target.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26

Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $25 to $26.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38

Oppenheimer analyst Jay Olson maintains Sagimet Biosciences (NASDAQ:SGMT) with a Outperform and raises the price target from $33 to $38.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27

Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and lowers the price target from $29 to $27.

Benzinga Newsdesk

PRO
Goldman Sachs Reinstates Sell on Sagimet Biosciences, Announces $7 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Sagimet Biosciences (NASDAQ:SGMT) with a Sell and announces $7 price target.

Benzinga Newsdesk

This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Analysts upgraded Sagimet, Figure, Illumina, Martin Marietta and Waters, raising price targets and improving ratings.

Avi Kapoor

Sagimet Biosciences Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Sagimet Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

PRO
Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26

PRO
Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38

PRO
Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27

PRO
Goldman Sachs Reinstates Sell on Sagimet Biosciences, Announces $7 Price Target

This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

People Also Watch

People Also Watch

Sagimet Biosciences Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Sagimet Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

PROGuggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26

PROOppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38

PROCitizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27

PROGoldman Sachs Reinstates Sell on Sagimet Biosciences, Announces $7 Price Target

This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

PRO
Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26

PRO
Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38

PRO
Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27

PRO
Goldman Sachs Reinstates Sell on Sagimet Biosciences, Announces $7 Price Target